

# Cancer/Tumor Profiling Market to Reach \$78.69 billion with 19.2% CAGR Forecast to 2022

Cancer/Tumor Profiling Market to Grow at a 19.2% CAGR Forecast to 2022

PUNE, INDIA, October 12, 2016 /EINPresswire.com/ -- According to researcher, the Global Cancer/Tumor Profiling market is expected to grow from \$23.04 billion in 2015 to reach \$78.69 billion by 2022 with a CAGR of 19.2%. Increasing cases of cancer and the need for therapy are the major factors influencing the market growth. Moreover, high investments in R&D, technological developments, and demand for safer medicines are the factors fostering the market growth. However, low awareness among clinicians about options and potential of cancer profiling are the major challenges for this market.

By application, personalized medicines segment leads the market globally with the biggest market share and is expected to grow with a



high CAGR during the forecast period. The growth is attributed by unique characteristics of this segment in examining and prognosis of cancer disease. North America commands the market due to the presence of leading cancer profiling industry leaders. Asia Pacific is expected to witness huge growth due to raising incidence of cancer in this region.

Request a sample report @ <a href="https://www.wiseguyreports.com/sample-request/674300-cancer-tumor-profiling-global-market-outlook-2016-2022">https://www.wiseguyreports.com/sample-request/674300-cancer-tumor-profiling-global-market-outlook-2016-2022</a>

Some of the key players in global Cancer/Tumor profiling market include Agendia Nv, Biotheranostics, Boreal Genomics, Inc., Caris Life Sciences, Genomic Health, Inc., Illumina, Inc., Life Technologies Corporation, Nanostring Technologies, Neogenomics Laboratories, Oncopath Laboratory, Oxford Gene Technology Ltd, Precision Therapeutics, Inc., Proteome Sciences Plc, Rational Therapeutics, and Ribomed Biotechnologies.

### **Applications Covered:**

- Biomarker Discovery
- Diagnostics
- Personalized Medicine
- Prognosis
- Research Applications

## Technologies Covered:

- Fluorescence/Chromogenic In Situ Hybridization
- Immunohistochemistry
- Microarray
- Next-Generation Sequencing
- Quantitative PCR

Get this report @ <a href="https://www.wiseguyreports.com/checkout?currency=one\_user-usb&report\_id=674300">https://www.wiseguyreports.com/checkout?currency=one\_user-usb&report\_id=674300</a>

What our report offers:

- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Key points in table of content 1 Executive Summary

2 Preface

- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
- 2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources

### 2.5.3 Assumptions

- 3 Market Trend Analysis
- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Application Analysis
- 3.7 Technology Analysis
- 3.8 Emerging Markets
- 4 Porters Five Force Analysis
- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry
- 5 Global Cancer/Tumor Profiling Market, By Application
- 5.1 Introduction
- 5.2 Biomarker Discovery
- 5.3 Diagnostics
- 5.4 Personalized Medicine
- 5.5 Prognosis
- 5.6 Research Applications
- 6 Global Cancer/Tumor Profiling Market, By Technology
- 6.1 Introduction
- 6.2 Fluorescence/Chromogenic In Situ Hybridization
- 6.3 Immunohistochemistry
- 6.4 Microarray
- 6.5 Next-Generation Sequencing
- 6.6 Quantitative PCR
- 7 Global Cancer/Tumor Profiling Market, By Geography
- 7.1 North America
- 7.1.1 US
- 7.1.2 Canada
- 7.1.3 Mexico
- 7.2 Europe
- 7.2.1 Germany
- 7.2.2 France

- 7.2.3 Italy
- 7.2.4 UK
- 7.2.5 Spain
- 7.2.6 Rest of Europe
- 7.3 Asia Pacific
- 7.3.1 Japan
- 7.3.2 China
- 7.3.3 India
- 7.3.4 Australia
- 7.3.5 New Zealand
- 7.3.6 Rest of Asia Pacific
- 7.4 Rest of the World
- 7.4.1 Middle East
- 7.4.2 Brazil
- 7.4.3 Argentina
- 7.4.4 South Africa
- 7.4.5 Egypt
- 8 Key Developments
- 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 8.2 Acquisitions & Mergers
- 8.3 New Product Launch
- 8.4 Expansions
- 8.5 Other Key Strategies
- 9 Company Profiling
- 9.1 Agendia Nv
- 9.2 Biotheranostics
- 9.3 Boreal Genomics, Inc.
- 9.4 Caris Life Sciences
- 9.5 Genomic Health, Inc.
- 9.6 Illumina, Inc.
- 9.7 Life Technologies Corporation
- 9.8 Nanostring Technologies
- 9.9 Neogenomics Laboratories
- 9.10 Oncopath Laboratory
- 9.11 Oxford Gene Technology Ltd
- 9.12 Precision Therapeutics, Inc.
- 9.13 Proteome Sciences Plc
- 9.14 Rational Therapeutics
- 9.15 Ribomed Biotechnologies

Complete report details @ https://www.wiseguyreports.com/reports/674300-cancer-tumor-

# profiling-global-market-outlook-2016-2022

Norah Trent wiseguyreports +1 646 845 9349 / +44 208 133 9349 email us here

This press release can be viewed online at: https://www.einpresswire.com/article/349008954

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.